It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Identify the mistake, adjust your plan, and implement corrective habits. This concise guide gives actionable steps to recover quickly and stay on track.
18,261 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Dell Technologies slid sharply on a broader AI rotation, yet fundamentals remained solid, prompting Jim Cramer to cal...
AscendEX ceased normal operations on July 1 as MiCA rules tightened, with withdrawal requests slowed or blocked. Zach...
As GenAI reshapes software, security becomes non-negotiable. Here are three cybersecurity stocks generative AI advoca...
As Buffett retires, Greg Abel takes the helm. Yet Berkshire’s quieter stock picker is delivering. This story breaks d...
Hycroft Mining stock dropped 18% this week as gold and silver prices slid and investors weighed development risk. Thi...
XRP’s on-exchange stock fell to a seven-year low while the price stayed rangebound. Analysts cite ETF custody moves a...
Super Micro Computer faces a looming risk of removal from the S&P 500 after prosecutors charged its co-founder and tw...
As air travel rebounds, investors weigh GE Aerospace against StandardAero. This guide breaks down business models, ri...
As AI workloads surge, hyperscalers turn to ASICs to cut costs. This deep dive compares Broadcom and Marvell, explain...
Tesla reports a record-breaking Q2, delivering 480,126 vehicles and signaling renewed momentum. Regional strength in ...
Meta is dialing back its grand metaverse bet. This pivot could reshape the company’s profits and the stock’s long-run...